A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.

被引：14
|
作者：
Burris, Howard A., III
Spira, Alexander I.
Taylor, Matthew H.
Yeku, Oladapo O.
Liu, Joyce F.
Munster, Pamela N.
Hamilton, Erika P.
Thomas, Jacob Stephen
Gatlin, Frances
Penson, Richard T.
Abrams, Thomas Adam
Dhawan, Mallika Sachdev
Walling, Jacqueline M.
Frye, John W.
Romanko, Kevin
Sung, Victoria
Brachmann, Carrie
El-Khoueiry, Anthony B.
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Tennessee Oncol PLLC, Nashville, TN USA
[3] Virginia Canc Specialists, US Oncol Res, Fairfax, VA USA
[4] Providence Canc Inst, Portland, OR USA
[5] Massachusetts Gen Hosp, Boston, MA 02114 USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
[8] USC, Div Oncol, Keck Sch Med, Norris Comprehens Canc Ctr, Los Angeles, CA USA
[9] Virginia Canc Specialist, Fairax, VA USA
[10] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[11] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA
[12] Arch Oncol, Brisbane, CA USA
[13] Univ Southern Calif, Los Angeles, CA 90007 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.2516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2516
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Highly Differentiated Anti-CD47 Antibody, AO-176, Potently Inhibits Hematologic Malignancies Alone and in Combination
    Richards, John
    Bouchlaka, Myriam N.
    Puro, Robyn J.
    Capoccia, Ben J.
    Hiebsch, Ronald R.
    Donio, Michael J.
    Wilson, W. Casey
    Chakraborty, Prabir
    Sung, Victoria
    Pereira, Daniel S.
    BLOOD, 2019, 134
  • [2] AO-176, a highly differentiated clinical stage anti-CD47 antibody, is efficacious in pre-clinical models of lymphoma.
    Capoccia, Benjamin J.
    Donio, Michael J.
    Richards, John O.
    Hiebsch, Ronald R.
    Puro, Robyn J.
    Kashyap, Arun K.
    Pereira, Daniel S.
    CANCER RESEARCH, 2021, 81 (13)
  • [3] AO-176, a highly differentiated humanized anti-CD47 antibody, exhibits single -agent and combination antitumor efficacy with chemotherapy and targeted antibodies
    Wilson, Casey
    Bouchlaka, Myriam
    Puro, Robyn
    Capoccia, Ben
    Hiebsch, Ronald
    Chakraborty, Prabir
    Donio, Michael
    Sung, Vicki
    Pereira, Daniel
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [4] A first-in-human study of MIL95, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors and lymphomas
    Zhang, Qingyuan
    Liu, Aiguo
    Shi, Jianhua
    Cai, Qingqing
    Qu, Zerui
    Liu, Sijun
    Song, Yuqin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] AO-176, a next-generation anti-CD47 antibody, induces immunogenic cell death
    Pereira, Daniel S.
    Capoccia, Benjamin J.
    Hiebsch, Ronald R.
    Donio, Michael J.
    Carter, Alun J.
    Puro, Robyn J.
    Wilson, W. Casey
    Manning, Pamela T.
    Carr, Robert W.
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [6] AO-176, A HIGHLY DIFFERENTIATED CLINICAL STAGE ANTI-CD47 ANTIBODY, PREFERENTIALLY BINDS TUMOR VERSUS NORMAL CELL CD47 WHEN COMPLEXED TO β1 INTEGRIN
    Puro, Robyn
    Chakraborty, Prabir
    Richards, John
    Hiebsch, Ronald
    Donio, Michael
    Wilson, W. Casey
    Capoccia, Benjamin
    Brachmann, Carrie
    Sung, Vicki
    Kashyap, Arun
    Pereira, Daniel
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A128 - A129
  • [7] FIRST-IN-HUMAN PHASE I TRIAL OF IBI188, AN ANTI-CD47 TARGETING MONOCLONAL ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS AND LYMPHOMAS
    Lakhani, Nehal
    Orloff, Marlana
    Fu, Siqing
    Liu, Ying
    Wang, Yan
    Zhou, Hui
    Lin, Kedan
    Liu, Fang
    Yan, Shuling
    Patnaik, Amita
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A180 - A180
  • [8] A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors.
    Subbiah, Vivek
    Vaishampayan, Ulka N.
    Puri, Sonam
    Lin, Lanjia
    Chao, Mark
    Ramsingh, Giri
    Kummar, Shivaani
    Strauss, James F.
    Patel, Sandip P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [9] AO-176, a Highly Differentiated Clinical Stage Anti-CD47 Antibody, Exerts Potent Anti-Tumor Activity in Preclinical Models of Multiple Myeloma As a Single Agent and in Combination with Approved Therapeutics
    Wilson, William Casey
    Richards, John
    Puro, Robyn J.
    Andrejeva, Gabriela
    Capoccia, Ben J.
    Donio, Mike J.
    Hiebsch, Ronald R.
    Chakraborty, Prabir
    Sung, Victoria
    Pereira, Daniel S.
    BLOOD, 2020, 136
  • [10] A FIRST-IN-HUMAN STUDY OF LEMZOPARLIMAB, A DIFFERENTIATED ANTI-CD47 ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY MALIGNANCY: INITIAL MONOTHERAPY RESULTS
    Berlin, Jordan
    Harb, Wael
    Adjei, Alex
    Xing, Yan
    Swiecicki, Paul
    Seetharam, Mahesh
    Nandagopal, Lakshminarayanan
    Gopal, Ajay
    Xu, Cong
    Meng, Yuan
    Lee, Linda
    Zhao, Yonggang
    Wang, Zhengyi
    Shen, Joan Huaqiong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A233 - A234
12345